Page last updated: 2024-11-08

hexacyanoferrate iii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hexacyanoferrate III: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439210
CHEBI ID5020
MeSH IDM0051406

Synonyms (13)

Synonym
CHEBI:5020
hexacyanidoferrate(iii)
hexazyanoferrat(iii)
hexacyanidoferrate(3-)
ferric hexacyanide
[fe(cn)6](3-)
hexacyanoferrate iii
13408-62-3
C00324
ferricyanide
hexacyanoferrate(iii)
hexacyanoiron(3-)
CRWNKXHVYMVLCY-UHFFFAOYSA-N

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, under aerobic conditions, AS was more toxic than under hypoxic conditions, suggesting that oxygen dramatically enhanced AS-mediated cytotoxicity."( The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO.
Chistodoulou, D; Cook, JA; DeGraff, WG; Feelisch, M; Fukuto, J; Gamson, J; Grisham, MB; Jourd'heuil, D; Kim, S; Krishna, M; Mitchell, JB; Vodovotz, Y; Wink, DA, 1998
)
0.3
" Toxicity assays measured the effect of toxic materials on the metabolic activity of microorganisms."( A sensitive, rapid and inexpensive way to assay pesticide toxicity based on electrochemical biosensor.
Dong, S; Liu, C; Yong, D; Yu, D, 2011
)
0.37
" Bioassay evaluation was performed using copper as model toxic agent."( Paper-based chromatic toxicity bioassay by analysis of bacterial ferricyanide reduction.
Bori, J; Fernández, M; Gómez, D; Guerrero-Navarro, A; Jiménez, S; Mas, J; Muñoz-Berbel, X; Pujol-Vila, F; Riva, MC; Vallès, B; Vigués, N, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
"In pharmacokinetic studies, a variety of analytical method including radioisotopic detection and HPLC (high performance liquid chromatography) has been used."( Pharmacokinetic analysis of free radicals by in vivo BCM (Blood Circulation Monitoring)-ESR method.
Sakurai, H; Takechi, K; Tamura, H; Yamaoka, K, 1997
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" We have characterized PCN or macrolides induced cytochromes P-450 by their specific ability to interact with macrolide derivatives and, using the cytochrome P-450 spectral binding assays, we have shown that some compounds, implicated in drug interaction with macrolides, interact preferentially with the same cytochromes."( Specific drug binding to rat liver cytochrome P-450 isozymes induced by pregnenolone-16 alpha-carbonitrile and macrolide antibiotics. Implications for drug interactions.
Delaforge, M; Sartori, E, 1990
)
0.28
" In order to remove the oxyanions from aqueous stream effectively, surfactant-modified powdered activated carbon (SM-PAC) combined with ultrafiltration (UF) was proposed in this study."( Removal of anionic contaminants by surfactant modified powdered activated carbon (SM-PAC) combined with ultrafiltration.
Hong, HJ; Kim, H; Lee, YJ; Yang, JW, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
"Native Cu,Zn-SOD and synthetic SOD mimics sometimes demonstrate an apparently anomalous bell-shaped dose-response relationship when protecting various biological systems from oxidative stress."( The pro-oxidative activity of SOD and nitroxide SOD mimics.
Offer, T; Russo, A; Samuni, A, 2000
)
0.31
" The proposed method was employed for the determination of CTP in bulk drug, in its pharmaceutical dosage forms and biological fluids such as human serum and urine."( Application of silver nanoparticles to the chemiluminescence determination of cefditoren pivoxil using the luminol-ferricyanide system.
Alarfaj, NA; Aly, FA; El-Tohamy, MF, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
4-amino-3-hydroxybenzoate degradation240
rutin degradation230

Research

Studies (647)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990153 (23.65)18.7374
1990's176 (27.20)18.2507
2000's166 (25.66)29.6817
2010's147 (22.72)24.3611
2020's5 (0.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.13 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index100.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (0.89%)6.00%
Case Studies1 (0.15%)4.05%
Observational0 (0.00%)0.25%
Other664 (98.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]